Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Our state-of-the-art technology, powered by artificial intelligence (AI), transforms both organized and disorganized healthcare information into a dependable, high-quality, standardized dataset that can be utilized throughout your organization. By facilitating near real-time access to data from various systems, our solutions alleviate the strain of manual data abstraction, enabling your administrative and clinical teams to reclaim valuable time for quality improvement and research endeavors. Our suite of products and services empowers you to gather, assess, and utilize your data effectively, irrespective of the data source, therapeutic area, organizational department, or pre-existing reporting, business intelligence, or analytics tools. Atlas leverages both human knowledge and AI capabilities to streamline the challenging process of uncovering and interpreting patient data for clinical registries. Meanwhile, Cartographer efficiently searches, evaluates, and interprets patient data across multiple platforms, standardizes that information into a uniform format, and offers pertinent data insights. Ultimately, our innovative solutions not only enhance operational efficiency but also support informed decision-making throughout your organization.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Carta Healthcare
Founded
2017
Country
United States
Website
www.carta.healthcare/
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/